Mylan
OVERALL |
|
Owned |
USA |
Rating |
![]() |
Pharmaceuticals
One the world's largest manufacturers of prescription generic drugs. Merged with Upjohn in 2020 to create Viatris Inc.
Company Ownership
Mylan NV | NLD | website | ||||
Viatris Inc ![]() owns 100% of Mylan NV |
USA | website | ||||
Pharmaceuticals Created in 2020 when Mylan merged with Pfizer's off-patent drug business, Upjohn. |
Company Assessment
PRAISE | CRITICISM | INFORMATION | ||
Mylan NV | ||||
In August 2017, Mylan agreed to a $465 million settlement in a whistleblower lawsuit. The U.S. Justice Department and several states claimed the company overcharged Medicaid for EpiPens. As part of the settlement, Mylan did not have to admit any wrongdoing. The settlement came as Mylan faced growing complaints about skyrocketing price hikes for EpiPens. Between 2007 and 2016, Mylan increased the price of a two-pack of EpiPens from less than $100 to more than $600.
Source: Drug Watch (2017)
Changing Markets' 2018 report, 'Hyderabad's Pharmaceutical Pollution Crisis' explores the impacts of pollution from pharmaceutical production sites in the Indian city of Hyderabad, one of the world's largest "bulk drug" manufacturing hubs. Water samples taken by investigators from factories owned by this company found the presence of solvents and/or heavy metals at extremely high concentrations, orders of magnitude higher than maximum regulatory limits or safe exposure levels, which points to substantial human and ecological risk potential.
Source: Changing Markets (2018)
In 2019 the median pay for a worker at this company was US$43,367. The CEO was paid 427 times this amount. Exorbitant CEO pay is a major contributor to rising inequality. CEOs are getting more because of their power to set pay, not because they are increasing productivity or possess specific, high-demand skills. The economy would suffer no harm if CEOs were paid less (or taxed more). In contrast, the CEO-to-typical-worker compensation ratio was 20-to-1 in 1965 and 58-to-1 in 1989.
Source: AFL-CIO (2020)
As You Sow's 2021 report, 'The 100 Most Overpaid CEOs', reveals the 100 most overpaid CEOs from USA's 500 largest public companies (as determined by the S&P 500 list). This company's CEO, Heather Bresch came in at number 21 on the list, having been paid US$18,509,260 in 2020. According to the report, "Most CEOs have come to be grossly overpaid, and that overpayment is harmful to the companies, the shareholders, the customers, the other employees, the economy, and society as a whole."
Source: As You Sow (2021) |
Mylan, the makers of the EpiPen, an injectable device that is filled with medicine and can stop a life-threatening allergic reaction with immediate effect, have increased the price of the device from $100 in 2008 to above $500 in 2016, making it a hike of over 400 per cent. Epipens only cost a few dollars to make and the price-hike has caused a public outcry.
Source: news article (2016) |
|||
Viatris Inc | ||||
In 2022, the Carbon Disclosure Project (CDP) asked companies to provide data about their efforts to reduce greenhouse gas emissions and mitigate climate change risk. Responding companies are scored across four key areas: disclosure; awareness; management; and leadership. This company received a CDP Climate Change Score of B-.
Source: CDP (2022)
The 2021 Antimicrobial Resistance (AMR) Benchmark ranks 17 large pharmaceutical companies on their efforts keep medicines and vaccines available, despite the rise of drug resistance. This company was identified as a leader amongst generic medicine manufacturers, receiving a score of 67%.
Source: Access to Medicine Foundation (2021)
In 2022, the Carbon Disclosure Project (CDP) asked companies to provide data about their efforts to manage and govern freshwater resources. Responding companies are scored on six key metrics: transparency; governance & strategy; measuring & monitoring; risk assessment; targets & goals; and value chain engagement. This company received a CDP Water Security Score of B.
Source: CDP (2022)
America's Most Responsible Companies 2022 by Newsweek and Statista recognises the Top 500 most responsible companies in the United States. Companies were evaluated in three areas: environmental (waste, energy use, etc.), social (leadership diversity, employees and philanthropy) and governance (transparency and economic performance). This company received a total score of 76.7/100, ranking 19th in the Health Care & Life Sciences sector, and 167th overall.
Source: Newsweek (2021) |
JUST Capital polls Americans every year to identify the issues that matter most in defining just business behaviour. For their 2023 rankings JUST Capital asked a representative sample of 3,002 Americans to compare 20 different business Issues on a head-to-head basis, producing a reliable hierarchy of Issues ranked in order of priority. Issues are organised under the headings Workers, Customers, Communities, the Environment, or Shareholders & Governance. JUST Capital then define metrics that map to those issues and track and analyse the largest, publicly traded U.S. companies. This analysis powers their rankings, in which this company ranked 827th of 951 companies, and 39th of 41 Pharmaceuticals & Biotech companies.
Source: JUST Capital (2023)
This company received an S&P Global ESG Score of 30/100 in the Pharmaceuticals category of the S&P Global Corporate Sustainability Assessment, an annual evaluation of companies' sustainability practices (last updated 18 Nov 2022). The rankings are based on an analysis of corporate economic, environmental and social performance, assessing issues such as corporate governance, risk management, environmental reporting, climate strategy, human rights and labour practices.
Source: S&P Global (2022) |
As You Sow's 2023 report, 'The 100 Most Overpaid CEOs', reveals the 100 most overpaid CEOs from USA's 500 largest public companies (as determined by the S&P 500 list). This company's CEO, Michael Goettler came in at number 53 on the list, having been paid US$14,669,592 in 2022. According to the report, "Most CEOs have come to be grossly overpaid, and that overpayment is harmful to the companies, the shareholders, the customers, the other employees, the economy, and society as a whole."
Source: As You Sow (2023)
This company is a member of the AMR Industry Alliance, a coalition of biotech, diagnostics, generics and research-based pharmaceutical companies set up to provide sustainable solutions to curb antimicrobial resistance (AMR). AMR is an increasingly significant threat to global public health which puts at risk the effective prevention and treatment of a wide range of infections.
Source: AMR Industry Alliance (2021)
This company has corporate social responsibility claims on its website.
Source: company website (2021)
California, the UK and Australia have all enacted legislation requiring companies operating within their borders to disclose their efforts to eradicate modern slavery from their operations and supply chains. Follow the link to see this company's disclosure statement.
Source: company website (2020)
OpenSecrets.org tracks the influence of money on U.S. politics, and how that money affects policy and citizens' lives. Follow link to see this company's record of political donations, lobbying, outside spending and more.
Source: Open Secrets (2020) |
Company Details
Type | Wholly-owned subsidiary |
Revenue | 7.7 billion USD (2014) |
Employees | 30,000 (2015) |
Subsidiaries | Meda AB ![]() Pharmaceutical manufacturer and marketer Products are prescription and OTC (over the counter) drugs. Main focus is on sales and marketing and as they do not develop early stage new products, new product growth is by acquisition. Products are sold in more than 150 countries, with own sales companies in 60 countries. Product areas are respiratory, dermatological and pain/inflammation. Acquired by Mylan in 2016. - Meda Pharmaceuticals Pty Ltd ![]() Pharmaceutical sales and marketing Over the counter products are Azep and Eyezep (allergic Rhinitis), Linicin (head lice), Molaxole (constipation), Waxsol (ear wax). Alphapharm Pty Ltd ![]() Pharmaceuticals Established in 1982. Makers of generic medicines. Alphapharm is the largest supplier of medicines to the government subsidised Pharmaceutical Benefits Scheme. Operates a manufacturing plant in Queensland. Acquired by Mylan in 2007 who merged with Upjohn in 2020 to form Viatris. Bought Aspen's portfolio of prescription and over-the-counter products in Australia for $188 million in 2019. |
Contact Details
Address | Amsterdam, Netherlands |
Website | www.mylan.com |
Products / Brands
Viatris Australia
Dermeze Skin Care Dermeze Body Wash Dymadon Pain Relief Tablets Gastro-Stop Digestive Care Irish Moss Cold & Flu Stingose Antiseptic Tums Digestive Care Waxsol Eye & Ear Care Zantac Digestive Care |